Origin Sciences

Executive Summary

Origin Sciences is a UK-based medical device and diagnostics company specializing in non-invasive gastrointestinal (GI) disease detection. Its proprietary OriCol device enables the collection of rectal mucosal samples, which serve as a novel biospecimen for highly accurate genomic and bioinformatic diagnostics. The company's research-driven laboratory applies advanced sequencing to uncover molecular mechanisms in GI and gynecological diseases. Founded in 2003 and headquartered in Cambridge, Origin Sciences operates in the Medical Devices and Diagnostics categories. While specific financial details, stage, and total funding are not publicly available, the company's innovative approach positions it to address a significant unmet need for early and accurate GI disease detection, potentially improving patient outcomes and reducing healthcare costs. The OriCol technology could disrupt current invasive screening methods, such as colonoscopy, by offering a simpler, less burdensome alternative.

Upcoming Catalysts (preview)

• Q4 2026CE Mark Approval for OriCol Device70% success
• Q2 2027Publication of Clinical Validation Study Results60% success
• Q1 2027Strategic Partnership with Diagnostic or Pharmaceutical Company50% success